Ticker > Company >

Aarti Drugs share price

Aarti Drugs Ltd.

NSE: AARTIDRUGS BSE: 524348 SECTOR: Pharmaceuticals & Drugs  1.85 L   953   231

510.85
+0.35 (0.07%)
BSE: 11 Sep 04:01 PM

Price Summary

Today's High

₹ 524.7

Today's Low

₹ 504.65

52 Week High

₹ 574.95

52 Week Low

₹ 312.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

4662.53 Cr.

Enterprise Value

5131.56 Cr.

No. of Shares

9.13 Cr.

P/E

26.04

P/B

3.59

Face Value

₹ 10

Div. Yield

0.2 %

Book Value (TTM)

₹  142.43

CASH

3.82 Cr.

DEBT

472.85 Cr.

Promoter Holding

55.22 %

EPS (TTM)

₹  19.62

Sales Growth

-9.25%

ROE

12.39 %

ROCE

13.7%

Profit Growth

-7.15 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-9.25%
3 Year5.79%
5 Year9.28%

Profit Growth

1 Year-7.15%
3 Year-18.04%
5 Year10.21%

ROE%

1 Year12.39%
3 Year16.11%
5 Year21.38%

ROCE %

1 Year13.7%
3 Year16.63%
5 Year20.91%

Debt/Equity

0.4024

Price to Cash Flow

13.83

Interest Cover Ratio

6.7965

CFO/PAT (5 Yr. Avg.)

1.00673031594346

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 55.22 0.00
Mar 2025 55.48 0.00
Dec 2024 55.38 0.00
Sep 2024 55.64 0.00
Jun 2024 55.67 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has a good cash flow management; CFO/PAT stands at 1.00673031594346.
  • The company has a high promoter holding of 55.22%.

 Limitations

  • The company has shown a poor profit growth of -18.0407372739959% for the Past 3 years.
  • The company has shown a poor revenue growth of 5.78643251336355% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 492.96 543.09 514.54 622.96 520.96
Total Expenditure 438.74 483.55 454.29 534.3 457.01
Operating Profit 54.22 59.54 60.25 88.66 63.95
Other Income 0.11 0.38 11.37 1.71 0.38
Interest 7.46 7.17 7.57 7.48 6.82
Depreciation 11.71 11.86 12.02 12.21 12.27
Exceptional Items 0 0 0 0 0
Profit Before Tax 35.16 40.89 52.03 70.68 45.24
Tax 8.25 10.5 13.5 9.2 -3.4
Profit After Tax 26.91 30.39 38.53 61.48 48.64
Adjusted EPS (Rs) 2.93 3.33 4.22 6.74 5.33

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1634.92 1914.89 2251.17 2497.97 2266.91
Total Expenditure 1386.98 1510.52 1930.01 2211.92 1997.74
Operating Profit 247.95 404.37 321.17 286.05 269.18
Other Income 1.06 6.42 4.77 2.23 4.18
Interest 35.74 25.71 23.05 36.18 33.21
Depreciation 46.67 47.6 47.39 47.29 47.67
Exceptional Items 8.38 0.22 0 0 0
Profit Before Tax 174.97 337.71 255.5 204.81 192.48
Tax 39.3 80 60.5 52 50.6
Net Profit 135.67 257.71 195 152.81 141.88
Adjusted EPS (Rs.) 14.56 27.65 21.06 16.5 15.43

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 23.3 93.2 92.6 92.6 91.94
Total Reserves 598.49 766.41 879.57 1021.7 1083.27
Borrowings 176.28 147.56 118.33 161.89 238.26
Other N/C liabilities 118.14 107.94 89.34 71.91 73.56
Current liabilities 554.49 521.89 854.68 847.39 684.6
Total Liabilities 1470.7 1637.01 2034.52 2195.5 2171.62
Assets
Net Block 611.57 630.52 649.41 634.48 722.29
Capital WIP 10.96 15.95 59.62 160.75 221.62
Intangible WIP 0 0 0 0 0
Investments 20.38 24.32 28.03 28.62 29.97
Loans & Advances 2.42 6.09 24.26 22.11 16.71
Other N/C Assets 0 0 0 0 0
Current Assets 825.36 960.13 1273.19 1349.53 1181.02
Total Assets 1470.7 1637.01 2034.52 2195.5 2171.62
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 174.97 337.71 255.5 204.81 192.48
Adjustment 79.82 65.35 66.76 78.43 77.69
Changes in Assets & Liabilities -21.34 -161.11 -202.27 -66.71 118.17
Tax Paid -37.32 -87.78 -80.09 -54.83 -51.23
Operating Cash Flow 196.15 154.18 39.9 161.7 337.1
Investing Cash Flow -29.35 -69.03 -125.36 -131.14 -187.09
Financing Cash Flow -167.76 -85.28 84.11 -30.54 -148.81
Net Cash Flow -0.96 -0.13 -1.35 0.03 1.2

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 55.67 55.64 55.38 55.48 55.22
aarnav rashesh gogri 0.20 0.20 0.20 0.20 0.20
aarti life science llp 0.01 0.01 0.01 0.01 0.01
aashay rashesh gogri 0.96 0.96 0.96 0.96 0.96
aashyav business trust (a... 1.50 1.50 1.50 1.50 1.50
adhish p. patil 1.24 1.24 1.24 1.25 1.25
alchemie financial servic... 0.04 0.04 0.04 0.04 0.04
alchemie finserv pvt. ltd... 2.21 2.21 2.21 2.21 2.21
anushakti enterprise priv... 2.62 2.62 2.62 2.62 2.62
arati tushar sankhe 0.19 0.19 0.19 0.19 0.19
arti rajendra gogri 0.15 0.15 0.15 0.15 0.15
arun moreshwar patil 0.08 0.08 0.08 0.08 0.08
bhoomi harshit savla 1.09 1.09 1.09 1.09 1.09
chandrakant vallabhaji go... 1.87 1.87 1.87 1.87 1.87
dilesh roadlines pvt ltd 0.54 0.54 0.54 0.54 0.54
gogri finserv pvt. ltd. 3.80 3.80 3.80 3.80 3.80
harshit m. savla (huf) (k... 0.01 0.01 0.01 0.01 0.01
harshit manilal savla 4.74 4.74 4.74 4.74 4.74
hetal gogri gala 3.06 3.05 3.05 3.05 3.05
hriman savla 0.02 0.02 0.01 0.01 0.01
indira madan dedhia 0.21 0.21 0.21 0.21 0.21
jay manilal savla 0.28 0.28 0.27 0.27 0.27
jaya chandrakant gogri 1.71 1.71 1.71 1.71 1.71
jigna hiren shah 0.50 0.50 0.50 0.50 0.50
kalika amit mishra 0.03 0.03 0.03 0.03 0.03
kenisha savla 0.02 0.02 0.01 0.01 0.01
manisha rashesh gogri 0.20 0.20 0.20 0.20 0.20
mirik rajendra gogri 0.80 0.80 0.70 0.70 0.70
orchid family trust (rela... 0.99 0.99 0.99 0.99 0.87
paridhi business trust (s... 0.64 0.64 0.64 0.64 0.64
prakash m. patil (huf) (k... 0.18 0.18 0.18 0.18 0.18
prakash moreshwar patil 9.24 9.23 9.23 9.32 9.32
priti prakash patil 4.40 4.40 4.40 4.40 4.40
rajendra vallabhaji gogri... 0.11 0.11 0.11 0.11 0.11
rashesh chandrakant gogri... 4.65 4.64 4.64 4.64 4.64
renil rajendra gogri 0.80 0.80 0.66 0.66 0.66
safechem enterprises priv... 0.61 0.61 0.61 0.61 0.61
seema harshit savla 3.84 3.84 3.84 3.84 3.84
tulip family trust (gloir... 1.01 1.01 1.01 1.01 0.88
uday moreshwar patil 0.06 0.06 0.06 0.06 0.06
vikas moreshwar patil 0.04 0.04 0.04 0.04 0.04
vishwa harshit savla 1.03 1.03 1.03 1.03 1.03
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 44.33 44.36 44.62 44.52 44.78
dsp small cap fund 5.64 5.93 6.45 7.13 7.98
harit pragji shah 2.67 2.67 2.67 2.67 2.67
icici prudential pharma h... - - 1.23 1.52 1.74
investor education and pr... 0.66 - - - 0.68
jayshree harit shah 1.79 1.79 1.78 1.78 1.78
llp 0.08 0.10 0.16 0.16 0.18
investor education and pr... - 0.67 0.68 0.68 -
blend fund 2 1.22 1.14 - - -
nikhil parimal desai 1.06 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
Credit CRISIL
Credit CRISIL
Credit
Credit
Credit
Credit
Credit
Credit ICRA
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research BP Wealth
Research Nuvama

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY25
Concall Q4FY24
Concall Q4FY21
Concall Q3FY25
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY22
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY23
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY24
Presentation Q1FY23
Presentation Q1FY22
Presentation Q1FY21
Presentation Q1FY19

Company News

Aarti Drugs Stock Price Analysis and Quick Research Report. Is Aarti Drugs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Aarti Drugs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Aarti Drugs has a PE ratio of 26.0673412688298 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Aarti Drugs has ROA of 6.4978% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Aarti Drugs has a Current ratio of 1.7251.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Aarti Drugs has a ROE of 12.3941%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Aarti Drugs has a Debt to Equity ratio of 0.4024 which means that the company has low proportion of debt in its capital.

  • Sales growth: Aarti Drugs has reported revenue growth of -9.2499% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Aarti Drugs for the current financial year is 11.8741252966481%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Aarti Drugs is Rs 1 and the yield is 0.1954%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Aarti Drugs is Rs 19.6165. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Aarti Drugs in Ticker for free. Also, one can get the intrinsic value of Aarti Drugs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Aarti Drugs FAQs

Q1. What is Aarti Drugs share price today?
Ans: The current share price of Aarti Drugs is Rs 511.35.

Q2. What is the market capitalisation of Aarti Drugs?
Ans: Aarti Drugs has a market capitalisation of Rs 4667.09145 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Aarti Drugs?
Ans: The PE ratio of Aarti Drugs is 26.0673412688298 and the P/B ratio of Aarti Drugs is 3.59009895150997, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Aarti Drugs share?
Ans: The 52-week high share price of Aarti Drugs is Rs 564.05, and the 52-week low share price of Aarti Drugs is Rs 312.

Q5. Does Aarti Drugs pay dividends?
Ans: Currently, Aarti Drugs pays dividends. Dividend yield of Aarti Drugs is around 0.1954%.

Q6. What are the face value and book value of Aarti Drugs shares?
Ans: The face value of Aarti Drugs shares is Rs 10, while the book value per share of Aarti Drugs is around Rs 142.4334. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Aarti Drugs?
Ans: Aarti Drugs has a total debt of Rs 472.8518 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Aarti Drugs?
Ans: The ROE of Aarti Drugs is 12.3941% and ROCE of Aarti Drugs is 13.697%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Aarti Drugs a good buy for the long term?
Ans: The Aarti Drugs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Aarti Drugs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Aarti Drugs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Aarti Drugs’s financials?
Ans: You can review Aarti Drugs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Aarti Drugs
X